Contact|Site Map|Search|Home
+News & Publications Home
+Press Releases
+Publications

Press Releases


10/17/08 Sirtris to Present at First Annual Boston Biotech R&D Conference
10/16/08 Sirtris CEO Christoph Westphal Selected by Biotech CEOs as Outstanding Individual
10/01/08 Sirtris’ Review of Sirtuin Therapeutics for Diseases of Aging in the Journal Nature Reviews Drug Discovery
09/16/08 Sirtris Completes Exclusive License to Harvard's SIRT3-Based Intellectual Property
07/03/08 Long-Term Study of Middle-Aged Mice Shows Resveratrol Improves Health and Mimics Some Benefits of Dietary Restriction
06/06/08 GlaxoSmithKline acquires Sirtris Pharmaceuticals, Inc., a world leader in sirtuin research and development
06/04/08 Sirtris Pharmaceuticals Presents at the American Diabetes Association’s 68th Annual Scientific Sessions June 8
06/02/08 GlaxoSmithKline Successfully Completes Tender Offer for Shares of Sirtris Pharmaceuticals
05/02/08 GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
05/01/08 Sirtris Pharmaceuticals Reports First Quarter 2008 Financial Results
04/22/08 GlaxoSmithKline to acquire Sirtris Pharmaceuticals, a world leader in 'Sirtuin' research and development
04/17/08 Sirtris Announces SRT501 Lowers Glucose in Twice-Daily Dosing Clinical Trial; Study Suggests Dose Response for Proprietary Formulation of Resveratrol in Type 2 Diabetics
04/16/08 Sirtris Scientific Advisory Board Co-Chairs Publish First In-Vivo Data Showing SIRT1 Enzyme Can Suppress Tumor Development
04/02/08 Sirtris Receives Orphan Drug Designation from U.S. Food and Drug Administration for Resveratrol in Mitochondrial Disorder, MELAS Syndrome
© 2008 Sirtris™ Pharmaceuticals All Rights Reserved. Terms of Use | Privacy Statement